• 1. Development of potent CPP6–gemcitabine conjugates against human prostate cancer cell line (PC-3)
  Cristiana Correia,Cristina P. R. Xavier,Diana Duarte,Abigail Ferreira,Sara Moreira,M. Helena Vasconcelos,Nuno Vale RSC Med. Chem. 2020 11 268
• 2. Modified nucleoside triphosphates in bacterial research for in vitro and live-cell applications
  Adeline Espinasse,Hannah K. Lembke,Angela A. Cao,Erin E. Carlson RSC Chem. Biol. 2020 1 333
• 3. Stent containing CD44-targeting polymeric prodrug nanoparticles that release paclitaxel and gemcitabine in a time interval-controlled manner for synergistic human biliary cancer therapy
  Dayeon Yun,Hyun-Ouk Kim,Hye Young Son,Yuna Choi,Ilkoo Noh,Jong-Woo Lim,Jihye Kim,Haejin Chun,Geunseon Park,Dong Ki Lee,Sung Il Jang,Eunji Jang,Yong-Min Huh,Seungjoo Haam J. Mater. Chem. B 2017 5 6317
• 4. Calcium-based biomaterials for diagnosis, treatment, and theranostics
  Chao Qi,Jing Lin,Lian-Hua Fu,Peng Huang Chem. Soc. Rev. 2018 47 357
• 5. Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood–brain barrier via carbon nitride dots
  Piumi Y. Liyanage,Yiqun Zhou,Abdulrahman O. Al-Youbi,Abdulaziz S. Bashammakh,Mohammad S. El-Shahawi,Steven Vanni,Regina M. Graham,Roger M. Leblanc Nanoscale 2020 12 7927

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidones

Introduction to 2'-Deoxy-2',2'-difluorocytidine 5'-triphosphate triethylammonium salt (CAS No. 110988-86-8)

2'-Deoxy-2',2'-difluorocytidine 5'-triphosphate triethylammonium salt, also known as ddFCtp, is a synthetic nucleoside triphosphate that has garnered significant attention in the field of medicinal chemistry and molecular biology. This compound is a modified version of cytidine, where the 2' position of the ribose sugar is substituted with two fluorine atoms. The triethylammonium salt form ensures its stability and solubility, making it a valuable tool in various biochemical and pharmaceutical applications.

The unique structure of ddFCtp confers it with distinct properties that set it apart from other nucleoside analogs. The fluorine substitutions at the 2' position significantly alter the conformation and electronic properties of the ribose sugar, leading to enhanced metabolic stability and reduced susceptibility to enzymatic degradation. These modifications also influence the compound's interactions with cellular machinery, particularly in the context of DNA and RNA synthesis.

In recent years, ddFCtp has been extensively studied for its potential therapeutic applications, particularly in the treatment of viral infections and cancer. One of the key areas of research has been its antiviral activity against RNA viruses, such as influenza and hepatitis C virus (HCV). Studies have shown that ddFCtp can effectively inhibit viral replication by incorporating into viral RNA, leading to premature chain termination and thus preventing the production of functional viral particles.

Beyond its antiviral properties, ddFCtp has also shown promise in cancer therapy. Research has demonstrated that this compound can selectively target rapidly dividing cancer cells by incorporating into their DNA during replication, leading to genomic instability and cell death. This selective toxicity towards cancer cells makes ddFCtp an attractive candidate for developing novel anticancer agents.

The mechanism of action of ddFCtp involves its incorporation into nucleic acids during biosynthesis. Once incorporated, the modified ribose sugar disrupts the normal base-pairing and backbone structure, leading to errors in DNA or RNA synthesis. This disruption can have profound effects on cellular processes, including transcription, translation, and replication. The triethylammonium salt form further enhances the compound's bioavailability and cellular uptake, ensuring that it reaches its intended targets efficiently.

In addition to its therapeutic potential, ddFCtp is also a valuable tool in basic research. Its unique properties make it an excellent substrate for studying nucleic acid metabolism and enzymatic processes. For instance, it can be used to investigate the fidelity of DNA polymerases and other enzymes involved in nucleic acid synthesis. The ability to introduce specific modifications into nucleic acids using compounds like ddFCtp opens up new avenues for understanding fundamental biological processes.

The synthesis of ddFCtp involves a series of well-defined chemical reactions that transform cytidine into its difluorinated derivative. The process typically begins with the protection of functional groups on cytidine to prevent unwanted side reactions. Subsequent steps include fluorination at the 2' position and conversion to the triphosphate form. The final step involves neutralization with triethylamine to form the triethylammonium salt, which is then purified and characterized using various analytical techniques such as NMR spectroscopy and mass spectrometry.

The stability and solubility of ddFCtp are critical factors that influence its utility in both research and therapeutic applications. The triethylammonium salt form ensures that the compound remains stable under a wide range of conditions, making it suitable for long-term storage and use in various experimental setups. Additionally, its solubility in aqueous solutions facilitates its incorporation into cell cultures and other biological systems.

In conclusion, 2'-Deoxy-2',2'-difluorocytidine 5'-triphosphate triethylammonium salt (CAS No. 110988-86-8), or ddFCtp, is a versatile compound with significant potential in both research and therapeutic applications. Its unique chemical structure endows it with enhanced metabolic stability and selective toxicity towards viral and cancer cells. Ongoing research continues to uncover new applications for this compound, further solidifying its importance in the fields of medicinal chemistry and molecular biology.

• 116371-67-6(Gemcitabine monophosphate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)